Protagonist Therapeutics, Inc (PTGX)
Pharmaceutical Preparations
Latest Price
$143.40
TTM P/E
139.22
Normalized P/E
--
Div Yield
--
Book Value
12.85
P/B Ratio
11.16
Valuation metrics
adjust assumptions →Base FCF: $119M (median of recent 5yr)
Growth: -15%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$17.04
88% downside
Institutional Ownership
100.0% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10.31M | $1.26B | 15.94% | +528.5K | 2026-06-30 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 6.35M | $778.0M | 9.82% | -- | 2026-06-30 |
| RTW INVESTMENTS, LP | 5.06M | $620.0M | 7.83% | +2.1K | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.63M | $444.0M | 5.61% | -- | 2026-06-30 |
| WELLINGTON MANAGEMENT GROUP LLP | 3.42M | $418.0M | 5.28% | -182.9K | 2026-06-30 |
| UBS Group AG | 3.40M | $416.0M | 5.26% | -1.78M | 2026-06-30 |
| STATE STREET CORP | 3.32M | $407.0M | 5.14% | +204.8K | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.85M | $349.0M | 4.41% | -- | 2026-06-30 |
| JOHNSON & JOHNSON | 2.45M | $300.0M | 3.79% | -- | 2026-06-30 |
| Invesco Ltd. | 2.34M | $286.0M | 3.62% | +176.0K | 2026-06-30 |